Different subtypes of carcinoma in situ of the bladder do not have a different prognosis | DocGuide
Pathologists need not include different subtypes of primary CIS in their report as there is no difference in patient outcomes. It is important to recognize all different subtypes as CIS for best patient treatment.
Přihlásit se k odběru:
Komentáře k příspěvku (Atom)
Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
článek zde Shan L, Liu W, Zhan Y. Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR in...
-
Different subtypes of carcinoma in situ of the bladder do not have a different prognosis | DocGuide Pathologists need not include differen...
-
MEDICAL TRIBUNE CZ > Metastázy uroteliálního karcinomu
Žádné komentáře:
Okomentovat